170 related articles for article (PubMed ID: 24634380)
1. Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer.
Roh JW; Huang J; Hu W; Yang X; Jennings NB; Sehgal V; Sohn BH; Han HD; Lee SJ; Thanapprapasr D; Bottsford-Miller J; Zand B; Dalton HJ; Previs RA; Davis AN; Matsuo K; Lee JS; Ram P; Coleman RL; Sood AK
Clin Cancer Res; 2014 May; 20(10):2740-50. PubMed ID: 24634380
[TBL] [Abstract][Full Text] [Related]
2. Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma.
Matsuo K; Nishimura M; Komurov K; Shahzad MM; Ali-Fehmi R; Roh JW; Lu C; Cody DD; Ram PT; Loizos N; Coleman RL; Sood AK
Gynecol Oncol; 2014 Jan; 132(1):166-75. PubMed ID: 24183729
[TBL] [Abstract][Full Text] [Related]
3. Targeting the {alpha} receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis.
Russell MR; Liu Q; Fatatis A
Clin Cancer Res; 2010 Oct; 16(20):5002-10. PubMed ID: 20813817
[TBL] [Abstract][Full Text] [Related]
4. Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target.
Loizos N; Xu Y; Huber J; Liu M; Lu D; Finnerty B; Rolser R; Malikzay A; Persaud A; Corcoran E; Deevi DS; Balderes P; Bassi R; Jimenez X; Joynes CJ; Mangalampalli VR; Steiner P; Tonra JR; Wu Y; Pereira DS; Zhu Z; Ludwig DL; Hicklin DJ; Bohlen P; Witte L; Kussie P
Mol Cancer Ther; 2005 Mar; 4(3):369-79. PubMed ID: 15767546
[TBL] [Abstract][Full Text] [Related]
5. Stromal platelet-derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenografts.
Gerber DE; Gupta P; Dellinger MT; Toombs JE; Peyton M; Duignan I; Malaby J; Bailey T; Burns C; Brekken RA; Loizos N
Mol Cancer Ther; 2012 Nov; 11(11):2473-82. PubMed ID: 22933705
[TBL] [Abstract][Full Text] [Related]
6. Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer.
Stock P; Monga D; Tan X; Micsenyi A; Loizos N; Monga SP
Mol Cancer Ther; 2007 Jul; 6(7):1932-41. PubMed ID: 17604334
[TBL] [Abstract][Full Text] [Related]
7. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma.
Yamada S; Imura Y; Nakai T; Nakai S; Yasuda N; Kaneko K; Outani H; Takenaka S; Hamada K; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
BMC Cancer; 2017 May; 17(1):334. PubMed ID: 28511645
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor α and bcr-abl oncogene addiction in malignant hematologic cells.
Wu Y; Chen C; Sun X; Shi X; Jin B; Ding K; Yeung SC; Pan J
Clin Cancer Res; 2012 Apr; 18(7):1966-78. PubMed ID: 22447844
[TBL] [Abstract][Full Text] [Related]
10. PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.
Thanapprapasr D; Previs RA; Hu W; Ivan C; Armaiz-Pena GN; Dorniak PL; Hansen JM; Rupaimoole R; Huang J; Dalton HJ; Ali-Fehmi R; Coleman RL; Sood AK
Mol Cancer Ther; 2015 Jun; 14(6):1466-1475. PubMed ID: 25833835
[TBL] [Abstract][Full Text] [Related]
11. Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.
Lowery CD; Blosser W; Dowless M; Knoche S; Stephens J; Li H; Surguladze D; Loizos N; Luffer-Atlas D; Oakley GJ; Guo Q; Iyer S; Rubin BP; Stancato L
Clin Cancer Res; 2018 Feb; 24(4):847-857. PubMed ID: 29191969
[No Abstract] [Full Text] [Related]
12. Imatinib mesylate inhibits androgen-independent PC-3 cell viability, proliferation, migration, and tumor growth by targeting platelet-derived growth factor receptor-α.
Nayeem MJ; Yamamura A; Hayashi H; Muramatsu H; Nakamura K; Sassa N; Sato M
Life Sci; 2022 Jan; 288():120171. PubMed ID: 34822800
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of platelet-derived growth factor receptor α by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer.
Laing N; McDermott B; Wen S; Yang D; Lawson D; Collins M; Reimer C; Hall PA; Andersén H; Snaith M; Wang X; Bedian V; Cao ZA; Blakey D
Mol Pharmacol; 2013 Jun; 83(6):1247-56. PubMed ID: 23558446
[TBL] [Abstract][Full Text] [Related]
14. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
Previs RA; Armaiz-Pena GN; Ivan C; Dalton HJ; Rupaimoole R; Hansen JM; Lyons Y; Huang J; Haemmerle M; Wagner MJ; Gharpure KM; Nagaraja AS; Filant J; McGuire MH; Noh K; Dorniak PL; Linesch SL; Mangala LS; Pradeep S; Wu SY; Sood AK
J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376174
[TBL] [Abstract][Full Text] [Related]
15. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
Ding C; Li L; Yang T; Fan X; Wu G
BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
[TBL] [Abstract][Full Text] [Related]
16. Autophagy inhibitor potentiates the antitumor efficacy of apatinib in uterine sarcoma by stimulating PI3K/Akt/mTOR pathway.
Chen S; Yao L
Cancer Chemother Pharmacol; 2021 Aug; 88(2):323-334. PubMed ID: 33978839
[TBL] [Abstract][Full Text] [Related]
17. Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β.
Bielen A; Perryman L; Box GM; Valenti M; de Haven Brandon A; Martins V; Jury A; Popov S; Gowan S; Jeay S; Raynaud FI; Hofmann F; Hargrave D; Eccles SA; Jones C
Mol Cancer Ther; 2011 Aug; 10(8):1407-18. PubMed ID: 21659463
[TBL] [Abstract][Full Text] [Related]
18. Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling.
Sang Y; Hou Y; Cheng R; Zheng L; Alvarez AA; Hu B; Cheng SY; Zhang W; Li Y; Feng H
Neuro Oncol; 2019 Nov; 21(11):1423-1435. PubMed ID: 31232447
[TBL] [Abstract][Full Text] [Related]
19. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.
Shen Y; Ren X; Ding K; Zhang Z; Wang D; Pan J
Oncotarget; 2014 Nov; 5(21):10407-20. PubMed ID: 25431951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]